Peptide and non-peptide antagonists targeting endothelin receptors in physiology and pathology

Current Pharmaceutical Design

Volumn 17, Issue 25, 2011, Pages 2613-2625

  Houde, Martin ^a   Labonté, Julie ^a   D'Orléans Juste, Pedro ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Antagonists; Endothelin 1; Receptors

Indexed keywords

2 (1,3 BENZODIOXOL 5 YL) 6 ISOPROPYL 4 (4 METHOXYPHENYL) 2H CHROMENE 3 CARBOXYLIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; A 182086; A 216546; ABT 546; ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; ANGIOTENSIN; ATRASENTAN; AVOSENTAN; BIG ENDOTHELIN 1; BMS 193884; BMS 207940; BOSENTAN; BQ 610; BRADYKININ; CLAZOSENTAN; CPU 0213; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO ALLO ISOLEUCYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO VALYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN 1 [11-21]; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FANDOSENTAN; IRL 2500; L 754142; LU 208075; MACITENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (HEXAHYDRO 1 AZEPINYLCARBONYL)LEUCYL(1 METHYL DEXTRO TRYPTOPHYL) DEXTRO TYROSINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; NEBENTAN; NEUROKININ; NITRIC OXIDE; PD 156252; PEPTIDE DERIVATIVE; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PROSTACYCLIN; RES 7011; RO 468443; SITAXSENTAN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TAK 044; TBC 3771; TEZOSENTAN; TTA 386; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

DRUG DEGRADATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HUMAN; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW;

EID: 80053527601     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797416101     Document Type: Review

References (160)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163): 411-5.
2. Ihara M, Ishikawa K, Fukuroda T, et al. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 1992; 20(Suppl 12): S11-4.
3. Roux S, Breu V, Ertel SI and Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999; 77(4): 364-76.
4. Valerio CJ and Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009; 5(1): 607-19.
5. Iglarz M and Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond) 2010; 119(11): 453-63.
6. Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther 2010; 27(5): 257-84.
7. Alvaro G and Di Fabio R. Neurokinin 1 receptor antagonists-- current prospects. Curr Opin Drug Discov Devel 2007; 10(5): 613-21.
8. Cosenzi A. Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovasc Hematol Agents Med Chem 2008; 6(2): 80-91.
9. Firszt R and Frank MM. An overview of novel therapies for acute hereditary angioedema. Am J Clin Dermatol 2010; 11(6): 383-8.
10. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86(8): 2863-7.
11. Warner TD, de Nucci G and Vane JR. Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol 1989; 159(3): 325-6.
12. Giaid A, Gibson SJ, Ibrahim BN, et al. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA 1989; 86(19): 7634-8.
13. Makita T, Sucov HM, Gariepy CE, Yanagisawa M and Ginty DD. Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons. Nature 2008; 452(7188): 759-63.
14. Laporte S, Denault JB, D'Orleans-Juste P and Leduc R. Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor. J Cardiovasc Pharmacol 1993; 22(Suppl 8): S7-10.
15. McMahon EG, Palomo MA, Moore WM, McDonald JF and Stern MK. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 1991; 88(3): 703-7.
16. De Lombaert S, Ghai RD, Jeng AY, Trapani AJ and Webb RL. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 1994; 204(1): 407-12.
17. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78(3): 473-85.
18. Mattera GG, Eglezos A, Renzetti AR and Mizrahi J. Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan. Br J Pharmacol 1993; 110(1): 331-7.
19. Takahashi M, Fukuda K, Shimada K, et al. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem J 1995; 311(Pt 2): 657-65.
20. Lindenau S, von Langsdorff C, Saxena A, Paul M and Orzechowski HD. Genomic organisation of the mouse gene encoding endothelin-converting enzyme-1 (ECE-1) and mRNA expression of ECE-1 isoforms in murine tissues. Gene 2006; 373(1): 109-15.
21. Valdenaire O and Schweizer A. Endothelin-converting enzyme-like 1 (ECEL1; 'XCE'): a putative metallopeptidase crucially involved in the nervous control of respiration. Biochem Soc Trans 2000; 28(4): 426-30.
22. Fernandez-Patron C, Radomski MW and Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85(10): 906-11.
23. Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000; 105(10): 1373-82.
24. Nakano A, Kishi F, Minami K, et al. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acidlength endothelins by chymase from human mast cells. J Immunol 1997; 159(4): 1987-92.
25. Simard E, Jin D, Takai S, et al. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 2009; 328(2): 540-8.
26. Fecteau M-H, Honoré J-C, Plante M, et al. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 2005; 46(1): 87--92.
27. Arai H, Hori S, Aramori I, Ohkubo H and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348(6303): 730-2.
28. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348(6303): 732-5.
29. Freedman NJ, Ament AS, Oppermann M, et al. Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J Biol Chem 1997; 272(28): 17734-43.
30. Telemaque S, Gratton JP, Claing A and D'Orleans-Juste P. Endothelin-1 induces vasoconstriction and prostacyclin release via the activation of endothelin ETA receptors in the perfused rabbit kidney. Eur J Pharmacol 1993; 237(2-3): 275-81.
31. Hirata Y, Yoshimi H, Takata S, et al. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 154(3): 868-75.
32. Haynes WG and Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344(8926): 852-4.
33. Whelchel A, Evans J and Posada J. Inhibition of ERK activation attenuates endothelin-stimulated airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1997; 16(5): 589-96.
34. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93(10): 1860-70.
35. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO, 3rd and Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33(2): 753-8.
36. de Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endotheliumderived relaxing factor. Proc Natl Acad Sci USA 1988; 85(24): 9797-800.
37. Lidbury PS, Thiemermann C, Thomas GR and Vane JR. Endothelin-3: selectivity as an anti-aggregatory peptide in vivo. Eur J Pharmacol 1989; 166(2): 335-8.
38. Clozel M, Gray GA, Breu V, Loffler BM and Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186(2): 867-73.
39. D'Orleans-Juste P, Claing A, Warner TD, Yano M and Telemaque S. Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. Br J Pharmacol 1993; 110(2): 687-92.
40. Johnson RJ, Fink GD and Galligan JJ. Mechanisms of endothelininduced venoconstriction in isolated guinea pig mesentery. J Pharmacol Exp Ther 1999; 289(2): 762-7.
41. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365(6448): 759-61.
42. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270(1): 228-35.
43. Warner TD, Allcock GH, Corder R and Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 1993; 110(2): 777-82.
44. Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999; 33(1 Pt 2): 581-5.
45. Kelland NF, Kuc RE, McLean DL, et al. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 2010; 88(6): 644-51.
46. Boulanger CM and Luscher TF. Differential effect of cyclic GMP on the release of endothelin-1 from cultured endothelial cells and intact porcine aorta. J Cardiovasc Pharmacol 1991; 17(Suppl 7): S264-6.
47. Rossi GP, Seccia TM and Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 2001; 209(1): 241-72.
48. Boulanger CM and Luscher TF. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res 1991; 68(6): 1768-72.
49. Gratton JP, Rae GA, Bkaily G and D'Orleans-Juste P. ET(B) receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit. Hypertension 2000; 35(3): 726-31.
50. Gratton JP, Cournoyer G, Loffler BM, Sirois P and D'Orleans-Juste P. ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997; 30(5): 1204-9.
51. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93(23): 13176-81.
52. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97(8): 752-6.
53. D'Orleans-Juste P, Labonte J, Duval M, Bkaily G and Berthiaume N. In: T. D. Warner, Ed. Endothelin and Its Inhibitors. Berlin: Springer-Verlag. 2000; pp.
54. Honore JC, Fecteau MH, Brochu I, et al. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster. Am J Physiol Heart Circ Physiol 2005; 289(3): H1258-64.
55. Montanari A, Biggi A, Carra N, et al. Endothelin-A receptors mediate renal hemodynamic effects of exogenous Angiotensin II in humans. Hypertension 2003; 42(4): 825-30.
56. Dumont Y, D'Amours M, Lebel M and Lariviere R. Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens 2001; 19(8): 1479-87.
57. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56(2): 714-9.
58. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI and van der Laarse A. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 2001; 218(1-2): 113-24.
59. Regoli D, Park WK and Rioux F. Pharmacology of angiotensin. Pharmacol Rev 1974; 26(2): 69-123.
60. Fournier A, Couture R, Magnan J, et al. Synthesis of peptides by the solid-phase method. V. Substance P and analogs. Can J Biochem 1980; 58(4): 272-80.
61. Regoli D and Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32(1): 1-46.
62. Saeki T, Ihara M, Fukuroda T, Yamagiwa M and Yano M. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun 1991; 179(1): 286-92.
63. Ihara M, Fukuroda T, Saeki T, et al. An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun 1991; 178(1): 132-7.
64. Watts SW. Endothelin receptors: what's new and what do we need to know? Am J Physiol Regul Integr Comp Physiol 2010; 298(2): R254-60.
65. Kishi F, Minami K, Okishima N, et al. Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun 1998; 248(2): 387--390.
66. Yoshizumi M, Kagami S, Suzaki Y, et al. Effect of endothelin-1 (1-31) on human mesangial cell proliferation. Jpn J Pharmacol 2000; 84(2): 146-55.
67. Lattig J, Oksche A, Beyermann M, Rosenthal W and Krause G. Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. J Pept Sci 2009; 15(7): 479-91.
68. Itoh S, Sasaki T, Ide K, et al. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 1993; 195(2): 969-75.
69. Ishikawa K, Fukami T, Nagase T, et al. In: C. H. Schneider and A. N. Eberle, Ed. Peptides. ESCOM Sciences Publishers EV. 1992; pp. 682-686
70. Sogabe K, Nirei H, Shoubo M, et al. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993; 264(3): 1040-6.
71. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin Breceptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91(11): 4892-6.
72. Takai M, Umemura I, Yamasaki K, et al. A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun 1992; 184(2): 953-9.
73. Ihara M, Saeki T, Fukuroda T, et al. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci 1992; 51(6): PL47-52.
74. Doherty AM, Cody WL, He JX, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol 1993; 22(Suppl 8): S98-102.
75. Kikuchi T, Ohtaki T, Kawata A, et al. Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB. Biochem Biophys Res Commun 1994; 200(3): 1708-12.
76. Bagnato A, Loizidou M, Pflug B, Curwen J and Growcott J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163(2):220-3.
77. Reriani M, Raichlin E, Prasad A, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010; 122(10): 958-66.
78. Stein PD, Hunt JT, Floyd DM, et al. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. J Med Chem 1994; 37(3): 329-31.
79. Chan MF, Okun I, Stavros FL, et al. Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem Biophys Res Commun 1994; 201(1): 228-34.
80. Iqbal J, Sanghi R and Das SK. Endothelin receptor antagonists: an overview of their synthesis and structure-activity relationship. Mini Rev Med Chem 2005; 5(4): 381-408.
81. Ohlstein EH, Nambi P, Douglas SA, et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994; 91(17): 8052-6.
82. Winn M, von Geldern TW, Opgenorth TJ, et al. 2,4- Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem 1996; 39(5): 1039-48.
83. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276(2): 473-81.
84. Battistini B, Berthiaume N, Kelland NF, Webb DJ and Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel -sentan class of drug. Exp Biol Med (Maywood) 2006; 231(6): 653-95.
85. Drake JM, Danke JR and Henry MD. Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer Biol Ther 2010; 9(8): 607-14.
86. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997; 40(11): 1690-7.
87. Riechers H, Albrecht HP, Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996; 39(11): 2123-8.
88. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283(3): 1110-8.
89. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011; 10(7): 618-25.
90. von Geldern TW, Tasker AS, Sorensen BK, et al. Pyrrolidine-3- carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem 1999; 42(18): 3668-78.
91. Clozel M and Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995; 26(Suppl 3): S262-4.
92. Michel RP, Langleben D and Dupuis J. The endothelin system in pulmonary hypertension. Can J Physiol Pharmacol 2003; 81(6): 542-54.
93. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. Jama 2007; 298(17): 2009-19.
94. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999; 290(2): 840-6.
95. Blandin V, Vigne P, Breittmayer JP and Frelin C. Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol 2000; 58(6): 1461-9.
96. Meens MJ, Compeer MG, Hackeng TM, et al. Stimuli of sensorymotor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes. PLoS One 2010; 5(6): e10917.
97. Hasselblatt M, Kamrowski-Kruck H, Jensen N, et al. ETA and ETB receptor antagonists synergistically increase extracellular endothelin-1 levels in primary rat astrocyte cultures. Brain Res 1998; 785(2): 253-61.
98. Sauvageau S, Thorin E, Caron A and Dupuis J. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 2006; 231(6): 840-6.
99. Zeng C, Asico LD, Yu C, et al. Renal D3 dopamine receptor stimulation induces natriuresis by endothelin B receptor interactions. Kidney Int 2008; 74(6): 750-9.
100. Curtis TM and Scholfield CN. Evidence for two endothelin Et(A) receptor subtypes in rabbit arteriolar smooth muscle. Br J Pharmacol 2001; 134(8): 1787-95.
101. Battistini B and Dussault P. Blocking of the endothelin system: the development of receptor antagonists. Pulm Pharmacol Ther 1998; 11(2-3): 97-112.
102. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327(3): 736-45.
103. Fabregat I and Rozengurt E. [D-Arg1,D-Phe5,DTrp7,9, Leu11]substance P, a neuropeptide antagonist, blocks binding, Ca2(+)-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells. J Cell Physiol 1990; 145(1): 88-94.
104. Spinella MJ, Malik AB, Everitt J and Andersen TT. Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction. Proc Natl Acad Sci USA 1991; 88(16): 7443-6.
105. Kojiri K, Ihara M, Nakajima S, et al. Endothelin-binding inhibitors, BE-18257A and BE-18257B. I. Taxonomy, fermentation, isolation and characterization. J Antibiot (Tokyo) 1991; 44(12): 1342-7.
106. Sakamoto A, Yanagisawa M, Tsujimoto G, et al. Pseudononcompetitive antagonism by BQ123 of intracellular calcium transients mediated by human ETA endothelin receptor. Biochem Biophys Res Commun 1994; 200(2): 679-86.
107. Balwierczak JL, Bruseo CW, DelGrande D, et al. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500. J Cardiovasc Pharmacol 1995; 26(Suppl 3): S393-6.
108. Aramori I, Nirei H, Shoubo M, et al. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 1993; 43(2): 127-31.
109. Buchan KW, Alldus C, Christodoulou C, et al. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br J Pharmacol 1994; 112(4): 1251-7.
110. Ihara M, Yamanaka R, Ohwaki K, et al. [3H]BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype. Eur J Pharmacol 1995; 274(1-3): 1-6.
111. Kitada C, Ohtaki T, Masuda Y, et al. Design and synthesis of ETA receptor antagonists and study of ETA receptor distribution. J Cardiovasc Pharmacol 1993; 22(Suppl 8): S128-31.
112. Pullen M, Brown G and Nambi P. Binding characteristics of [125I]TTA 386, ETA-selective antagonist. Neuropeptides 1997; 31(4): 345-9.
113. Peter MG and Davenport AP. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol 1995; 114(2): 297-302.
114. Urade Y, Fujitani Y, Oda K, et al. An endothelin B receptorselective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21). FEBS Lett 1992; 311(1): 12-6.
115. Tanaka T, Tsukuda E, Nozawa M, et al. RES-701-1, a novel, potent, endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol 1994; 45(4): 724-30.
116. Nambi P, Elshourbagy N, Wu HL, et al. Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 1994; 271(2): 755-61.
117. Russell FD and Davenport AP. Characterization of the binding of endothelin ETB selective ligands in human and rat heart. Br J Pharmacol 1996; 119(4): 631-6.
118. Reynolds EE, Hwang O, Flynn MA, et al. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995; 209(2): 506-12.
119. Watanabe T, Awane Y, Ikeda S, et al. Pharmacology of a nonselective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995; 114(5): 949-54.
120. Masuda Y, Sugo T, Kikuchi T, et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]- L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucylD-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 1996; 279(2): 675-85.
121. Cody WL, He JX, Reily MD, et al. Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac- DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties. J Med Chem 1997; 40(14): 2228-40.
122. Webb ML, Bird JE, Liu EC, et al. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1995; 272(3): 1124-34.
123. Krystek SR, Jr., Patel PS, Rose PM, et al. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. J Biol Chem 1994; 269(17): 12383-6.
124. Mihara S, Nakajima S, Matumura S, Kohnoike T and Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. J Pharmacol Exp Ther 1994; 268(3): 1122-8.
125. Russell FD and Davenport AP. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. J Cardiovasc Pharmacol 1995; 26(Suppl 3): S346-7.
126. Doherty AM, Patt WC, Edmunds JJ, et al. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptorselective antagonists. J Med Chem 1995; 38(8): 1259-63.
127. Wanecek M, Oldner A, Sundin P, et al. Effects on haemodynamics by selective endothelin ET(B) receptor and combined endothelin ET(A)/ET(B) receptor antagonism during endotoxin shock. Eur J Pharmacol 1999; 386(2-3): 235-45.
128. Reynolds EE, Keiser JA, Haleen SJ, et al. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. J Pharmacol Exp Ther 1995; 273(3): 1410-7.
129. Vatter H, Zimmermann M, Jung C, et al. Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery. Clin Sci (Lond) 2002; 103(Suppl 48): 408S-413S.
130. Jensen N, Hasselblatt M, Siren AL, et al. ET(A) and ET(B) specific ligands synergistically antagonize endothelin-1 binding to an atypical endothelin receptor in primary rat astrocytes. J Neurochem 1998; 70(2): 473-82.
131. Bradbury RH, Bath C, Butlin RJ, et al. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-Npyridyl-,- N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1- naphthalenesulfonamides. J Med Chem 1997; 40(6): 996-1004.
132. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005; 92(12): 2148-52.
133. Liu G, Henry KJ, Jr., Szczepankiewicz BG, et al. Pyrrolidine-3- carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546). J Med Chem 1998; 41(17): 3261-75.
134. Wu-Wong JR, Dixon DB, Chiou WJ, et al. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor. Eur J Pharmacol 1999; 366(2-3): 189-201.
135. Bialecki RA, Stinson-Fisher C, Murdoch W, et al. A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat. Chest 1998; 114(1 Suppl): 91S.
136. Wilson C, Hunt SJ, Tang E, et al. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1999; 290(3): 1085-91.
137. Ohlstein EH, Nambi P, Hay DW, et al. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 1998; 286(2): 650-6.
138. Murugesan N, Gu Z, Stein PD, et al. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308). J Med Chem 1998; 41(26): 5198-218.
139. Coe Y, Haleen SJ, Welch KM and Coceani F. The endothelin-Areceptor antagonist PD 180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb. J Cardiovasc Pharmacol 2000; 36(5 Suppl 1): S331-3.
140. Coe Y, Haleen SJ, Welch KM, Liu YA and Coceani F. The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther 2002; 302(2): 672-80.
141. Ishizuka N, Matsumura K, Sakai K, et al. Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2- (benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2Hchromene-3 -carboxylic acid (S-1255). 1. Study on structureactivity relationships and basic structure crucial for ET(A) antagonism. J Med Chem 2002; 45(10): 2041-55.
142. Iwasaki T, Mihara S, Shimamura T, et al. Pharmacologic characterization of S-1255, a highly potent and orally active endothelin A receptor antagonist. J Cardiovasc Pharmacol 2001; 37(4): 471-82.
143. Harada H, Kazami J, Watanuki S, et al. Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists. Bioorg Med Chem 2001; 9(11): 2955-68.
144. Yuyama H, Sanagi M, Koakutsu A, et al. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist. Eur J Pharmacol 2003; 478(1): 61-71.
145. Perreault T, Berkenbosch JW, Barrington KJ, et al. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res 2001; 50(3): 374-83.
146. Wu C, Decker ER, Blok N, et al. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4- dimethylisoxazol-5-ylsulfamoyl)thio phene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. J Med Chem 2004; 47(8): 1969-86.
147. Murugesan N, Gu Z, Spergel S, et al. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5- dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-bi phenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem 2003; 46(1): 125-37.
148. Hulpke-Wette M and Buchhorn R. BMS-193884 and BMS-207940 Bristol-Myers Squibb. Curr Opin Investig Drugs 2002; 3(7): 1057-61.
149. Dieterle W, Mann J and Kutz K. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol 2004; 44(1): 59-66.
150. Breu V, Clozel M, Burri K, et al. In vitro characterisation of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ETB receptor. FEBS Lett 1996; 383(1-2): 37-41.
151. Douglas SA. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci 1997; 18(11): 408-12.
152. Breu V, Loffler BM and Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett 1993; 334(2): 210-4.
153. Williams DL, Jr., Murphy KL, Nolan NA, et al. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther 1995; 275(3): 1518-26.
154. Jae HS, Winn M, Dixon DB, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists. J Med Chem 1997; 40(20): 3217-27.
155. Wu-Wong JR, Dixon DB, Chiou WJ, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 2002; 103(Suppl 48): 107S-111S.
156. Hoshino T, Yamauchi R, Kikkawa K, Yabana H and Murata S. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998; 286(2): 643-9.
157. Takahashi M, Taniguchi T, Tanaka T, et al. Pharmacological characterization of TA-0201, an endothelin receptor antagonist,with recombinant and human prostate endothelin receptors. Eur J Pharmacol 2003; 467(1-3): 185-9.
158. Nishikibe M, Ohta H, Okada M, et al. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther 1999; 289(3): 1262-70.
159. Qi MY, Xia HJ, Dai DZ and Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47(6): 729-35.
160. Li N, Jia N, Dai DZ and Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591(1-3): 211-8.